BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...by HBM Healthcare Investments to advance lead product ARQ-151, a topical formulation of PDE-4 inhibitor roflumilast...
BioCentury | Oct 22, 2019
Financial News

Crossover investors help Arcutis raise $95M to advance PDE-4 inhibitor for psoriasis

...series C financing to advance lead product ARQ-151, a topical formulation of the PDE-4 inhibitor roflumilast...
...from AstraZeneca plc (LSE:AZN; NYSE:AZN) to roflumilast for topical uses. Roflumilast is approved orally as Daliresp...
BioCentury | Jul 22, 2019
Clinical News

July 22 Clinical Quick Takes: Positive psoriasis data for Arcutis; plus Intec and Renovo

...to start a Phase III trial in 1Q20 of the topical reformulation of PDE-4 inhibitor roflumilast...
BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

...an exclusive, worldwide license from AstraZeneca plc for topical uses. Roflumilast is approved orally as Daliresp...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Transplant

...AstraZeneca plc, Allergan plc, Merck & Co. Inc. and Mitsubishi Tanabe Pharma Corp. market Daliresp roflumilast...
BioCentury | Mar 21, 2017
Distillery Therapeutics

Pulmonary

...Allergan plc , Merck & Co. Inc. and Mitsubishi Tanabe Pharma Corp. market Daliresp roflumilast...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

...attract the best talent." In respiratory, Takeda marketed chronic obstructive pulmonary disease (COPD) drug Daliresp roflumilast...
BioCentury | Dec 21, 2015
Company News

Takeda, AstraZeneca deal

...AstraZeneca will acquire Takeda’s core respiratory business, including Daliresp roflumilast, Alvesco ciclesonide, Omnaris ciclesonide nasal spray...
...200 staff to AZ. The deal is slated to close next quarter. AZ already markets Daliresp...
BioCentury | Dec 17, 2015
Top Story

AZ bulks up China operations, respiratory portfolio

...China (see BioCentury, May 11) . The Takeda deal gives AZ ex-U.S. rights to Daxas roflumilast...
...roflumilast to treat COPD. AZ already markets the non-steroidal phosphodiesterase-4 ( PDE-4 ) inhibitor as Daliresp...
...ciclesonide nasal spray to treat allergic rhinitis, and undisclosed preclinical programs. Excluding U.S. sales of Daliresp...
BioCentury | Feb 23, 2015
Clinical News

Daliresp roflumilast: Phase III/IV data

...double-blind, international Phase III/IV REACT trial in 1,945 patients showed that 500 µg daily oral Daxas...
...EU and Canada as Daxas to treat severe COPD associated with chronic bronchitis. Takeda gained Daxas...
...Tokyo:4508), Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Daliresp roflumilast (Daxas-EU) ( APTA-2217...
Items per page:
1 - 10 of 125